Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 101(10): 1740-8, 2009 Nov 17.
Article in English | MEDLINE | ID: mdl-19844236

ABSTRACT

BACKGROUND: Although the aetiology of prostate cancer remains unknown, we hypothesised that chronic bacterial insult has a major role in prostate carcinogenesis. METHODS: Male C3H/HeOuJ mice, infected with phosphate-buffered saline or Escherichia coli bacteria, were killed at 5 days, or at 12 or 26 weeks. Harvested prostate tissues were evaluated for inflammatory responses and immunostained for neoplastic transformation markers. RESULTS: All infected mice developed bacterial prostatitis. Control mice had no prostate infections or inflammation. Mice infected for 5 days showed foci of acute inflammation with infiltrating neutrophils and epithelial necrotic debris in the prostatic glandular lumen. All mice infected for 12 weeks had evidence of chronic inflammation with dense inflammatory infiltrates in the stroma. The prostatic epithelium showed varying degrees of atypical hyperplasia with increased epithelial cell layers and cytological atypia. At 26 weeks, the dysplastic changes were more pronounced and mimicked a prostatic intraepithelial neoplasia and high-grade dysplasia. Prostatic glands exhibiting reactive dysplasia had a stronger staining for oxidative DNA damage, increased epithelial cell proliferation, and a decrease in androgen receptor, GSTP1, p27(Kip1), and PTEN expression, when compared with control prostate glands. CONCLUSION: These data demonstrate that chronic inflammation induces focal prostatic glandular atypia and suggest a potential linkage between inflammation and prostatic neoplasia.


Subject(s)
Prostatic Intraepithelial Neoplasia/microbiology , Prostatic Neoplasms/microbiology , Prostatitis/pathology , Animals , Cell Growth Processes/physiology , Disease Models, Animal , Epithelial Cells/pathology , Escherichia coli Infections/metabolism , Escherichia coli Infections/pathology , Immunohistochemistry , Male , Mice , Mice, Inbred C3H , Prostatic Intraepithelial Neoplasia/pathology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Prostatitis/metabolism , Prostatitis/microbiology
2.
J Pharmacol Exp Ther ; 289(2): 649-55, 1999 May.
Article in English | MEDLINE | ID: mdl-10215635

ABSTRACT

The interaction of interleukin-2 (IL-2) with its receptor (IL-2R) decreases cytochrome P-450 (CYP) expression in rat hepatocytes. Because IL-2 increases c-Myc in lymphocytes and because c-myc overexpression represses several genes, we postulated that the IL-2/IL-2R interaction may increase c-Myc and thereby down-regulate CYP in hepatocytes. Cultured rat hepatocytes were exposed for 24 h to IL-2 (350 U/ml) and other agents. IL-2 increased c-myc mRNA and protein but decreased total CYP and the mRNAs and proteins of CYP2C11 and CYP3A. The IL-2-mediated c-myc overexpression and CYP down-regulation were prevented by 1) genistein (a tyrosine kinase inhibitor that blocks the initial transduction of the IL-2R signal), 2) retinoic acid, butyric acid, or dimethyl sulfoxide (three agents that block c-myc transcription), or 3) an antisense c-myc oligonucleotide (which may cause rapid degradation of the c-myc transcript). It is concluded that IL-2 causes the overexpression of c-myc and the down-regulation of CYPs in rat hepatocytes. Block of c-myc overexpression, at three different levels with five different agents, prevents CYP down-regulation, suggesting that c-myc overexpression may directly or indirectly repress CYP in hepatocytes.


Subject(s)
Cytochrome P-450 Enzyme System/biosynthesis , Gene Expression Regulation , Interleukin-2/physiology , Liver/enzymology , Proto-Oncogene Proteins c-myc/biosynthesis , Animals , Blotting, Northern , Butyric Acid/pharmacology , Cells, Cultured , Cytochrome P-450 Enzyme System/genetics , Dimethyl Sulfoxide/pharmacology , Down-Regulation , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Humans , Immunohistochemistry , Interleukin-2/pharmacology , Liver/cytology , Liver/drug effects , Lymphocytes/cytology , Lymphocytes/drug effects , Lymphocytes/metabolism , Male , Oligonucleotides, Antisense/pharmacology , Precipitin Tests , Proto-Oncogene Proteins c-myc/genetics , Rats , Rats, Sprague-Dawley , Tretinoin/pharmacology
3.
Biochem Pharmacol ; 57(8): 951-4, 1999 Apr 15.
Article in English | MEDLINE | ID: mdl-10086330

ABSTRACT

Interleukin-2 (IL-2) has been shown to decrease cytochrome P450 (CYP) mRNAs and proteins in cultured rat hepatocytes, and IL-2 administration decreases CYPs in rats. Although high doses of IL-2 are administered to cancer patients, the effect on human CYPs has not yet been determined. Patients with hepatic metastases from colon or rectum carcinomas were randomly allocated to various daily doses of human recombinant IL-2 (from 0 to 12.10(6) units/m(2)). IL-2 was infused from day 7 to day 3 before hepatectomy and the conservation of a non-tumorous liver fragment in liquid nitrogen. Hepatic CYPs and monooxygenase activities were not significantly decreased in 5 patients receiving daily doses of 3 or 6 10(6) IL-2 units/m2, compared to 7 patients who did not receive IL-2. In contrast, in 6 patients receiving daily doses of 9 or 12 x 10(6) IL-2 units/m2, the mean values for immunoreactive CYP1A2, CYP2C, CYP2E1, and CYP3A4 were 37, 45, 60 and 39%, respectively, of those in controls; total CYP was significantly decreased by 34%, methoxyresorufin O-demethylation by 62%, and erythromycin N-demethylation by 50%. These observations suggest that high doses of IL-2 may decrease total CYP and monooxygenase activities in man.


Subject(s)
Adenocarcinoma/enzymology , Antineoplastic Agents/pharmacology , Colonic Neoplasms/enzymology , Cytochrome P-450 Enzyme System/metabolism , Interleukin-2/pharmacology , Liver Neoplasms/enzymology , Rectal Neoplasms/enzymology , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Antineoplastic Agents/therapeutic use , Colonic Neoplasms/therapy , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 CYP3A , Enzyme Repression , Humans , Immunotherapy , Interleukin-2/therapeutic use , Liver Neoplasms/immunology , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Mixed Function Oxygenases/metabolism , Rectal Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...